The Good, the Bad and the Ugly of the NIHSS: Time for a Change?

August 31, 2021
The NIHSS remains the fundamental assessment of stroke severity. However, some have called for modifying the NIHSS to better capture disability. Is it time to change the NIHSS?
0 Comments

What Else Beyond the NIHSS Should We Be Doing Clinically?

August 24, 2021
The NIHSS was a research tool meant to limit variability and provide uniform quantifiable assessments  of stroke severity.  As the de facto standard for stroke exams and scores, it has withstood the test of time.  However, there is more to the assessment of acute stroke severity and this podcast takes a deep dive into what else we need to be doing besides the NIHSS.
0 Comments

The Clock Is Dead - The Reign of Tissue Imaging

August 17, 2021
Mismatch is your friend if you want to treat acute stroke patients beyond 3 hrs. While the clock was once the king, tissue imaging may now define what brain is salvageable and what has been lost. Listen here and see if you agree that the clock is dead in stroke.
0 Comments

Defining the SOC - Is 4.5 Hrs the Real Answer?

August 10, 2021
The standard of care can feel elusive. Listen here as Dr. Knight shares his expertise regarding the definition of the SOC in extended window therapy for tPA. It's not a simple question and Dr. Knight is the one to answer it.
0 Comments

How Do I Identify Patients at Risk for a Secondary Event Following an Initial Acute Ischemic Stroke?

August 3, 2021
Identification of patients at high risk for secondary ischemic event, after initial event or post TIA...is minimal tissue damage really that big of a deal related to secondary stroke? Drs. Galen Henderson of Brigham and Women’s Hospital and Jordan Bonomo of the University of Cincinnati discuss key perspectives from a neurocritical, emergency medicine, and stroke perspective related to this important area of medicine.
0 Comments
RSS
123578910Last
Categories
More Entries

Dec 4

What Was Missing From the NINDS Trial?

Brian Gibler posted on 12/4/2020

Moderator: Jordan Bonomo, MD, FCCM, FNCS
Other Participants: Opeolu Adeoye, MD, MS FACEP, FAHA

The NINDS trial was the seminal study of IV-tPA in the treatment of acute stroke. Yet controversy still exists around the trial methodology and the interpretation of the data. Was anything missing from NINDS? Does it still resonate nearly 25 years later?

Dr. Opeolu (Ope) Adeoye sits down with Dr. Jordan Bonomo and shares his immense expertise in clinical trialing. As a researcher carrying over $30M in research funding, Dr. Adeoye is an internationally recognized stroke trialist and methodologist. In this podcast, he talks about the challenges of the NINDS trial, what was really well done and what could have been different. “Time critical diagnosis” is the term he wields in this exciting and thought provoking podcast.

0 Comments
Please login or register to post comments.